🟢 Solid Biosciences is trading 5% up on October 27 with no clear catalyst identified

Solid Biosciences is trading at $6.12, up 5.27%, with no clear catalyst identified for the October 27 move.

• On October 26, the company announced EU orphan designation for SGT-212 and reported five FALCON trial participants dosed without treatment-related serious adverse events as of October 5.
• Seven research posters are scheduled for the October 27–30 gene and cell therapy congress, but no source linked them directly to the gain.
• The broad market picture was mixed, making an index-wide explanation uncertain.